We assessed if STK25 deletion status has an effect on the clinical course of disease and found that sarcoma patients with STK25 deletions have significantly shorter durations of survival and that deletions of STK25 are more common in patients with recurrent disease than those without (Fig. 7c, Supplementary Fig. 7a). The gene discussed is STK25; the disease is sarcoma.